Background
Autoinflammatory disease: recurrent episodes of inflammatory lesions in association with signs of systemic inflammation ex: FMF, TNF receptor-associated periodic syndrome, hyper IgD syndrome Cryopyrin-associated syndromes -arise from abnormalities in the control of IL1B, caused by mutations in the NLRP3 gene which encodes the NALP3 protein NALP3 forms a complex that activates caspase 1, which cleaves inactive IL1B into its active form Anakinra (recombinant human IL-1-receptor antagonist) -blocks the proinflammatory effects of IL1B and blocks systemic inflammation in patients with cryopyrin-associated periodic syndrome 9 patients with an autoinflammatory syndrome of skin and bone caused by recessive mutations in IL1RN (gene encoding the IL1-receptor antagonist)
IL1 and the IL1 receptor antagonist
IL1 is a highly active proinflammatory cytokine that causes fever, anorexia, and tissue damage/remodeling, elevated markers of systemic inflammation IL1RN is structurally similar to IL1B, the antagonist binds to the IL1 receptor thereby blocking access of IL1 to the receptor both are produced in patients with infection, trauma, or inflammatory conditions and compete for the IL1 Receptor animal studies indicate that severity of inflammation is influenced by the IL1/IL1RN balance Methods all protocols approved by IRBs, informed consent obtained empiric treatment with anakinra was initiated in all patients at a dose of 1mg/kg subQ dose was increased to titrate to a CRP < 0.5mg/dL and ESR<15mm/hr functional assays were conducted on blood from patients, siblings, parents, and controls 
Characteristics of Study Patients and Their Clinical Disease

Structural Consequences of the IL1RN Mutations
A. DIRA results in premature truncation of the IL1R amino acid sequence, residues 1-25 represent a segnal peptide that is cleaved when secreted.
IL1RN Mutations
all nine patients were homozygous for IL1RN mutation (7 pts) or parents were heterozygous carriers (2 pts) mutations included deletions, frame shift mutations, incorporation of aberrant amino acids and termination codons, and nonsense mutations none of these mutations were found in DNA specimens obtained from a panel of 364 white control from the New York Cancer Project frequency of each mutation was tested in DNA samples from controls from the patient's country of origin (except the Lebanese family) 2/555 controls from Newfoundland carried the mutation from patient 1 0/351 Dutch controls carried the same mutation as the Dutch patients, all three unrelated Dutch families were geographically matched and carried the same mutation strongly suggesting a founder effect 3/119 Puerto Rican controls carried the same mutation as the Puerto Rican patient who came from a genetically isolated population 
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